Javascript must be enabled to continue!
P53 MINIMALLY INVASIVE TECHNIQUES FOR TRANSTHORACIC ESOPHAGECTOMY FOR ESOPHAGEAL CANCERS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
View through CrossRef
Abstract
Aim
To evaluate the clinical outcomes for open, minimally invasive and robotic esophagectomy techniques for esophageal cancers.
Background & Methods
Esophagectomy is a demanding operation which can be performed by employing different approaches including open surgery or a combination of minimal access techniques. Each approach has specific reported advantages and disadvantages. A systematic literature search was conducted for studies reporting open, laparoscopic hybrid esophagectomy (LHE), thoracoscopic hybrid esophagectomy (THE), totally minimally invasive esophagectomy (MIE) or robotic MIE (RoMIE) for esophagectomy. A network meta-analysis of intraoperative (operating time, blood loss), postoperative (overall complications, anastomotic leaks, chyle leak, length of hospital stay), oncological outcomes (R0 resection, lymphadenectomy) and survival were performed.
Results
Ninety-eight studies including 32,296 patients were included in the network meta-analysis, of which 55% (n=17824), 5% (n=1576), 7% (n=2421), 30% (n=9558) and 3% (n=917) were open, LHE, THE, MIE and RoMIE respectively. Both MIE and RoMIE were associated with less blood loss, significantly lower rates of pulmonary complications, shorter length of stay and higher lymph node yield. There were no significant differences between surgical techniques for surgical site infections, chyle leak, and 30-day and 90-day mortality. MIE and RoMIE had better 1-year and 5-year survival rates compared to open respectively.
Conclusion
Minimally invasive and robotic techniques for esophagectomy are associated with reduced perioperative morbidity and length of stay with no compromise on oncological outcomes but no improvement in perioperative mortality. There are suggestions of improved long-term survival with MIE and RoMIE but these associations are not consistent across 1-, 3- and 5-year survival.
Oxford University Press (OUP)
Title: P53 MINIMALLY INVASIVE TECHNIQUES FOR TRANSTHORACIC ESOPHAGECTOMY FOR ESOPHAGEAL CANCERS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Description:
Abstract
Aim
To evaluate the clinical outcomes for open, minimally invasive and robotic esophagectomy techniques for esophageal cancers.
Background & Methods
Esophagectomy is a demanding operation which can be performed by employing different approaches including open surgery or a combination of minimal access techniques.
Each approach has specific reported advantages and disadvantages.
A systematic literature search was conducted for studies reporting open, laparoscopic hybrid esophagectomy (LHE), thoracoscopic hybrid esophagectomy (THE), totally minimally invasive esophagectomy (MIE) or robotic MIE (RoMIE) for esophagectomy.
A network meta-analysis of intraoperative (operating time, blood loss), postoperative (overall complications, anastomotic leaks, chyle leak, length of hospital stay), oncological outcomes (R0 resection, lymphadenectomy) and survival were performed.
Results
Ninety-eight studies including 32,296 patients were included in the network meta-analysis, of which 55% (n=17824), 5% (n=1576), 7% (n=2421), 30% (n=9558) and 3% (n=917) were open, LHE, THE, MIE and RoMIE respectively.
Both MIE and RoMIE were associated with less blood loss, significantly lower rates of pulmonary complications, shorter length of stay and higher lymph node yield.
There were no significant differences between surgical techniques for surgical site infections, chyle leak, and 30-day and 90-day mortality.
MIE and RoMIE had better 1-year and 5-year survival rates compared to open respectively.
Conclusion
Minimally invasive and robotic techniques for esophagectomy are associated with reduced perioperative morbidity and length of stay with no compromise on oncological outcomes but no improvement in perioperative mortality.
There are suggestions of improved long-term survival with MIE and RoMIE but these associations are not consistent across 1-, 3- and 5-year survival.
Related Results
063. ROBOTIC ASSISTED MIMINALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY VERSUS CONVENTIONAL MINIMALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY
063. ROBOTIC ASSISTED MIMINALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY VERSUS CONVENTIONAL MINIMALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY
Abstract
Background
Minimally invasive technique for esophagectomy has emerged as the standard of care for resectable esophageal...
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract
The physiological mechanisms that can restore biological activity of mutant p53 is an area of high interest given that mutant p53 expression is observed in ...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract
Although the main function of p53 is a nuclear transcription factor that has important roles in cell cycle arrest, DNA repair, and apoptosis, p53 can direct...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 1716: A small molecule corrector for p53 mutants found in cancer
Abstract 1716: A small molecule corrector for p53 mutants found in cancer
Abstract
p53 is the main tumor suppressor protein in vertebrates and the most frequently mutated gene in human cancers. The majority of p53 mutations are missense mu...

